CAS: 195514-63-7; (1R,1'R)-((((Ethane-1,2-Diylbis(Azanediyl))Bis(2-Oxoethane-2,1-Diyl))Bis(Oxy))Bis(3,1-Phenylene))Bis(3-(3,4-Dimethoxyphenyl)Propane-1,1-Diyl) (2S,2'S)-Bis(1-((S)-2-(3,4,5-Trimethoxyphenyl)Butanoyl)Piperidine-2-Carboxylate)

该化合物是复杂的有机化合物,其特点是分子结构错综复杂.这种物质具有多种功能性,包括酯类,氨类和芳香环,有助于其潜在的生物活动和化学再活动.三氧基苯基苯基和氟氧基苯基甲基基甲酯的存在表明,可能与生物目标发生相互作用,使其对医药化学特性产生兴趣.其管状和丁酸成分成分可能会影响其药性特性,例如溶性和易性.由(S)配置所显示的化合物具有多种功能化学特性,在这种化学特性中往往具有关键的特性特性特性.

结构式图片

上下游产品

2-(3-((R)-3-(3,4-Dimethoxyphenyl)-1-(((S)-1-((S)-2-(3,4,5-Trimethoxyphenyl)Butanoyl)Piperidine-2-Carbonyl)Oxy)Propyl)Phenoxy)Acetic Acid 195514-23-9

合成工艺路线路线简述

    📜(R)-1-(3-(2-(Tert-Butoxy)-2-Oxoethoxy)Phenyl)-3-(3,4-Dimethoxyphenyl)Propyl (S)-1-((S)-2-(3,4,5-Trimethoxyphenyl)Butanoyl)Piperidine-2-Carboxylate 以55的收率获得2,2'-[1,2-乙二基双[亚氨基(2-氧代-2,1-乙二基)氧基-3,1-亚苯基[(1R)-3-(3,4-二甲氧基苯基)亚丙基]]]二[(2S)-1-[(2S)-1-氧代-2-(3,4,5-三甲氧基苯基)丁基]-2-哌啶甲酸]
    参考文献:一种合成s-1-[(S)-2-(3,4,5-三甲氧苯基)丁酰基]哌啶-2-羧酸的方法
    标题:一种合成s-1-[(S)-2-(3,4,5-三甲氧苯基)丁酰基]哌啶-2-羧酸的方法
    摘要:本发明公开了一种合成s-1-[(S)-2-(3,4,5-三甲氧苯基)丁酰基]哌啶-2-羧酸的方法.采用消旋的2-(3,4,5-三甲氧苯基)丁酸与手性的s-哌啶-2-羧酸甲酯发生缩合和水解后得到非对映异构体(R,S)-型ⅱ'和(S,S)-型ⅱ,利用该非对映异构体酸与手性的r-苯乙胺成盐速度的差别,成功地将非对映异构体进行了有效成盐拆分分离,成盐后加入酸,将拆分剂去除后得到所需要构型的(S,S)-型化合物ⅱ.母液加碱回流后,又可以将非需要的构型再次转变成非对映异构体原料,循环利用.

    专利信息


    专利号:US-12031126-B2
    优先权日:2020-05-08
    标 题 :Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
    发明人:LIU DAVID R; ANZALONE ANDREW VITO; LEVY JONATHAN MA; GAO XIN; PODRACKY CHRISTOPHER J
    权利人:BROAD INST INC; HARVARD COLLEGE
    摘要:The present disclosure provides systems, compositions, and methods for simultaneously editing both strands of a double-stranded DNA sequence at a target site to be edited. In some aspects, the systems comprise a first and second prime editor complex, wherein each of the first and second prime editor complexes comprises (1) a prime editor comprising (i) a nucleic acid programmable DNA binding protein (napDNAbp), and (ii) a polypeptide having an RNA-dependent DNA polymerase activity; and (2) a pegRNA comprising a spacer sequence, gRNA core, a DNA synthesis template, and a primer binding site, wherein the DNA synthesis template encodes a desired DNA sequence or a complement thereof, wherein the desired DNA sequence and the complement thereof form a duplex comprising an edited portion which integrates into the target site to be edited. In some aspects, the systems comprise a first, second, third, and fourth prime editor complex, each comprising a prime editor and a PEgRNA. Also provided herein are methods for simultaneously editing both strands of a double-stranded DNA sequence at a target site to be edited. Further provided herein are pharmaceutical compositions, polynucleotides, vectors, cells, and kits.

    专利号:US-12281303-B2
    优先权日:2019-03-19
    标 题 :Methods and compositions for prime editing nucleotide sequences
    发明人:LIU DAVID R; ANZALONE ANDREW VITO; NELSON JAMES WILLIAM
    权利人:BROAD INST INC; HARVARD COLLEGE
    摘要:Compositions and methods are provided herein for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and/or targeted mutagenesis. The compositions include fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a modified guide RNA, named an PEgRNA. The PEgRNA has been altered (relative to a standard guide RNA) to comprise an extended portion that provides a DNA synthesis template sequence which encodes a single strand DNA flap which is synthesized by the polymerase of the fusion protein and which becomes incorporated into the target DNA molecule.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Zheng Y, Nandakumar KS, Cheng K. Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches. J Med Chem. 2021 Jul 22;64(14):9577-9591. doi: 10.1021/acs.jmedchem.0c02054. Epub 2021 Jun 30. 28(12):1365-1375. doi: 10.1038/s41417-020-00284-3. Epub 2021 Jan 7.
    3: Amatya C, Pegues MA, Lam N, Vanasse D, Geldres C, Choi S, Hewitt SM, Feldman SA, Kochenderfer JN. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7. Mol Ther. 2021 Feb 3;29(2):702-717. doi: 10.1016/j.ymthe.2020.10.008. Epub 2020 Oct 14.
    4: Wang X, Jasinski DL, Medina JL, Spencer DM, Foster AE, Bayle JH. Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells. Blood Adv. 2020 May 12;4(9):1950-1964. doi: 10.1182/bloodadvances.2020001510.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知